Aurealis Therapeutics Announces Positive Blinded Evaluator Efficacy Results of “DIAMEND” Phase-2 Randomized Controlled Trial: AUP-16 Tripling the Complete Wound Closure Rate in Patients with Chronic Diabetic Foot Ulcers

Aurealis Therapeutics Announces Positive Blinded Evaluator Efficacy Results of “DIAMEND” Phase-2 Randomized Controlled Trial: AUP-16 Tripling the Complete Wound Closure Rate in Patients with Chronic Diabetic Foot Ulcers Zug Switzerland and Kuopio Finland – December 4th, 2025. Aurealis Therapeutics, a clinical-stage company developing scalable and low COGS multi-target cell and gene therapies for chronic wounds […]